Sucampo Pharmaceuticals (NASDAQ: SCMP) (SPI) today announced that RESCULA (unoprostone
isopropyl ophthalmic solution) 0.15% is now available by prescription
across the United States. The U.S. Food and Drug Administration (FDA)
approved a sNDA for RESCULA for the lowering of intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension on
December 7, 2012.

“RESCULA is an important prostone-based treatment option for patients
suffering from open-angle glaucoma, which is the most common form of
glaucoma,” said Sucampo’s Chairman, Chief Executive Officer, and Chief
Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. “We have already
received positive feedback from many in the ophthalmology and optometry
communities regarding RESCULA’s unique mechanism of action

See full press release

Posted in: News, Guidance, Management, Global